美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

iShares Health Innovation Active ETF

33.56

0.0000

成交量：58

成交額：1,973.62

市值：1,342.44萬

市盈率：- -

高：33.56

開：33.56

低：33.56

收：33.56

52周最高：34.86

52周最低：25.79

股本：40.00萬

流通股本：40.00萬

量比：0.65

換手率：0.01%

股息：0.08

股息率：0.24%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

甘李藥業(603087.SH)：GZC8072片Ⅰ期臨床試驗完成首例受試者給藥

2026年國家醫保談判在北京啓動；珍視明回應滴眼液抽檢不合格事件 | 醫藥早參

每日经济新闻

「很緊張，汗都出來了！」直擊2025年國家醫保談判首日：中藥企業打頭陣

2026年國家醫保談判開啓！早8點代表入場，多家中藥企業亮相

「該給我個交代！」易慕峯臨床試驗受試者死亡，董事讓記者「滾開」，15天前啱啱遞表，對話家屬還原經過

廣生堂：GST-Peak-Triple臨床試驗首例成功入組

長春高新(000661.SZ)子公司GenSci133注射液臨床試驗申請獲得批准

長春高新：子公司GenSci133注射液臨床試驗申請獲批准

默沙東PD-1抑制劑可瑞達局部晚期頭頸鱗癌適應症在華獲批

Stoke Therapeutics與渤健在第16屆歐洲癲癇大會上公布Zorevunersen長期臨床數據，力證Dravet綜合徵治療藥物的疾病修飾潛力

印度西普拉（Cipla）與中國齊魯製藥合作，在美國推出默克公司Keytruda的生物類似藥

艾伯維公布CERVINO三期臨床試驗取得積極主要終點數據。

中國生物製藥(01177.HK)：TQB6426「GPC3 ADC」臨床試驗申請獲FDA批准

中國生物製藥：附屬公司正大天晴自主研發的國家1類新藥TQB6426臨床試驗申請獲FDA批准

ST人福：RFUS-949片進入II期臨床試驗研究

甘李藥業(603087.SH)獲得GZC8072片新適應症《藥物臨床試驗批准通知書》

甘李藥業：GZC8072片獲2型糖尿病臨床試驗批准

ST人福(600079.SH)：RFUS-949片進入II期臨床試驗研究

瑞銀上調強生目標價至320美元

強生(JNJ)股票9月2日開盤上漲3.15%：釋放什麼信號？

TradingKey中文

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/BMED/news?page=7"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"BMED","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","market":"US","secType":"STK","nameCN":"iShares Health Innovation Active ETF","latestPrice":33.5609,"timestamp":1789655075724,"preClose":33.5609,"halted":0,"volume":58,"delay":0,"changeRate":0,"floatShares":400000,"shares":400000,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"09-17 10:29:14 EDT","open":33.5609,"high":33.5609,"low":33.5609,"amount":1973.61878,"amplitude":0,"askPrice":34.11,"askSize":1000,"bidPrice":34.03,"bidSize":1000,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789675200000},"marketStatusCode":2,"adr":0,"exchange":"ARCA","adjPreClose":33.5609,"sharesOutstanding":360000,"nav":33.339378,"aum":13335751.2,"dividendRate":0.002375,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":33.41,"preClose":33.5609,"latestTime":"16:10 EDT","volume":6,"amount":201.3654,"timestamp":1789589403907,"change":-0.1509,"changeRate":-0.004496,"amplitude":0},"volumeRatio":0.653833,"impliedVol":0.0628,"impliedVolPercentile":0.004},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BMED\",,,,,undefined,":{"symbol":"BMED","floatShares":400000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.653833,"shares":400000,"dividePrice":0.0797,"high":33.5609,"amplitude":0,"preClose":33.5609,"low":33.5609,"week52Low":25.794,"pbRate":"--","week52High":34.86,"institutionHeld":0,"latestPrice":33.5609,"eps":0,"divideRate":0.002375,"volume":58,"delay":0,"ttmEps":0,"open":33.5609,"prevYearClose":30.32,"prevWeekClose":32.965,"prevMonthClose":33.8091,"prevQuarterClose":30.62,"fiveDayClose":32.8027,"twentyDayClose":34.7939,"sixtyDayClose":28.39},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BMED\",params:#limit:5,,,undefined,":[{"date":"2026-06-15","symbol":"BMED","amount":0.08118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-15","defaultRemindTime":1781530200000,"name":"iShares Health Innovation Active ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-18","payableDate":"2026-06-15","currency":"USD","dateTimestamp":1781496000000,"payDate":"2026-06-18"},{"date":"2023-12-20","symbol":"BMED","amount":0.007207,"announcedDate":"2023-12-20","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"BlackRock Future Health ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BMED\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.007207,"currency":"USD"},{"executeDate":"2026-06-15","recordDate":"2026-06-15","paymentDate":"2026-06-18","value":0.08118,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BMED\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BMED\",pageSize:20,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665397088","title":"甘李藥業(603087.SH)：GZC8072片Ⅰ期臨床試驗完成首例受試者給藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2665397088","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665397088?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 15:52","pubTimestamp":1788767548,"startTime":"0","endTime":"0","summary":"智通财经APP讯，甘李药业 发布公告，公司全资子公司甘李药业山东有限公司自主研发的GZC8072片正在中国开展Ⅰ期临床试验，于近日成功完成首例受试者给药。GZC8072片是新一代偏向型超长效多肽口服周制剂，正在开展用于肥胖或超重、2型糖尿病的适应症的临床试验。据悉，该产品于2026年8月、9月分别获得国家药品监督管理局下发的适应症为肥胖或超重、2型糖尿病的《药品临床试验批准通知书》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492741.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","IBBJ","MDTX","IBBQ","PSYK","BMED","603087"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665367071","title":"2026年國家醫保談判在北京啓動；珍視明回應滴眼液抽檢不合格事件 | 醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2665367071","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665367071?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 07:01","pubTimestamp":1788735712,"startTime":"0","endTime":"0","summary":"丨2026年9月7日星期一丨NO.12026年国家医保谈判在北京启动9月5日，2026年国家医保目录谈判竞价和商保创新药目录价格协商在北京启动，预计持续4至5天。新版目录有望于11月底前公布，2027年1月1日起执行。与往年相比，今年国谈整体提前约一个月，已有59个创新药完成参考药预沟通，并新增创新药“预申报”。点评：预沟通与预申报缩短创新药准入周期，有利于药企加快商业化节奏。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609073866183218.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609073866183218.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1515","PBPH","159938","BMED","09939","XLVI","BK1161","APXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665636842","title":"「很緊張，汗都出來了！」直擊2025年國家醫保談判首日：中藥企業打頭陣","url":"https://stock-news.laohu8.com/highlight/detail?id=2665636842","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665636842?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 16:59","pubTimestamp":1788598790,"startTime":"0","endTime":"0","summary":"9月5日早上8时，2026年国家基本医保药品目录谈判竞价及商保创新药目录价格协商工作在北京市西城区全国人大会议中心启动，时代周报记者前往现场了解情况。谈判开始之前，已有数十名药企代表在全国人大会议中心门口等候。8时左右，国家医保局工作人员在会议中心门口点名药企代表进入，8:08左右所有参加上午场谈判的药企代表完成入场。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609053866015465.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609053866015465.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BMED","XLVI","APXH","PBPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665712357","title":"2026年國家醫保談判開啓！早8點代表入場，多家中藥企業亮相","url":"https://stock-news.laohu8.com/highlight/detail?id=2665712357","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665712357?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 09:47","pubTimestamp":1788572828,"startTime":"0","endTime":"0","summary":"本文来源：时代周报2026年国家基本医保药品目录谈判竞价及商保创新药目录价格协商工作，于9月5日早8点在北京市西城区全国人大会议中心启动。时代周报记者从现场了解到，早8点左右，国家医保局工作人员开始在会议中心门口点名药企代表进入；8:08左右所有参加上午场谈判的药企代表完成入场。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609053865981910.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609053865981910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["XLVI","PBPH","BMED","APXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664137336","title":"「該給我個交代！」 易慕峯臨床試驗受試者死亡，董事讓記者「滾開」，15天前啱啱遞表，對話家屬還原經過","url":"https://stock-news.laohu8.com/highlight/detail?id=2664137336","media":"BUG","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664137336?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 18:47","pubTimestamp":1788518820,"startTime":"0","endTime":"0","summary":"9月2日，时代周报记者就易慕峰生物科技股份有限公司临床试验受试者死亡事件致电该公司董事李某昕，得到了这样的回应。本次死亡可能属于SAE严重不良事件。后来其丈夫占某签字同意加入这个临床试验。医院与药方对该事件的口径一致，患者脑出血是化疗药物副作用所致，与试验药物无关。程女士反复表示，无法接受医院和药企对占某参加临床试验突然死亡事件的解释。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-09-04/doc-iniqskus1166780.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IPOS","PSYK","IBBQ","IBBJ","BMED","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664335039","title":"廣生堂：GST-Peak-Triple臨床試驗首例成功入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2664335039","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664335039?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 18:27","pubTimestamp":1788517656,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","IBBQ","GST","PSYK","BMED","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664938709","title":"長春高新(000661.SZ)子公司GenSci133注射液臨床試驗申請獲得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664938709","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664938709?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 16:22","pubTimestamp":1788510145,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)发布公告，近日，公司控股子公司长春金赛药业有限责任公司(简称“金赛药业”)收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，金赛药业GenSci133注射液的境内生产药品注册临床试验申请获得批准。据悉，GenSci133注射液是金赛药业自主研发的一款甲状旁腺激素(PTH)类似物与抗核因子κB受体活化因子配体(RANKL)抗体融合蛋白，属于治疗用生物制品1类，拟用于治疗骨质疏松症。如子公司临床试验申请进展顺利，将有利于公司拓宽业务结构、优化产品结构，并丰富完善内分泌代谢领域产品线布局、提升公司核心竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492053.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0057","BMED","BK0046","BK0188","BK0075","IBBQ","PSYK","BK0239","000661","BK0028","MDTX","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664462387","title":"長春高新：子公司GenSci133注射液臨床試驗申請獲批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664462387","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664462387?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 16:12","pubTimestamp":1788509543,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BMED","IBBJ","IBBQ","MDTX","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664496800","title":"默沙東PD-1抑制劑可瑞達局部晚期頭頸鱗癌適應症在華獲批","url":"https://stock-news.laohu8.com/highlight/detail?id=2664496800","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664496800?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 08:43","pubTimestamp":1788482626,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0070302665.USD","SG9999014567.USD","LU1035773651.USD","LU0266013472.USD","IE00BN8TJ469.HKD","IYH","LU0006306889.USD","LU0965508806.USD","LU1162221912.USD","LU2089984988.USD","LU1069347547.HKD","LU0208291251.USD","LU1291159041.SGD","IHE","LU2461242641.AUD","LU0203345920.USD","LU1923622614.USD","LU1066051498.USD","LU2433249047.HKD","LU0238689110.USD","LU2023250504.SGD","LU2125154935.USD","LU0965509010.AUD","LU1037948897.HKD","LU1201861249.SGD","LU1989771016.USD","LU2361044865.SGD","TRUH","LU1974910355.USD","IE00BJT1NW94.SGD","SGXZ57979304.SGD","IE00BFTCPJ56.SGD","SG9999015341.SGD","LU1699723380.USD","LU2491050154.USD","FTXH","BK4559","LU0823416689.USD","LU1983299246.USD","LU1023059063.AUD","LU1941712264.USD","LU1116320901.HKD","SG9999001176.SGD","GDOC","LU2361044949.HKD","LU1585245621.USD","LU0234572021.USD","LU2491049909.HKD","LU0130517989.USD","PAWZ","LU0648001328.SGD","LU0320765489.SGD","BMED","VHT","LU2023250843.SGD","LU2361045086.USD","LU1093756325.SGD","RXL","IE00B4R5TH58.HKD","LU0320765646.SGD","LU2125909593.SGD","LU2360032135.SGD","LU0965509283.SGD","LU0965509101.SGD","IE0002141913.USD","LU0980610538.SGD","LU1057294990.SGD","IE00B2B36J28.USD","LU1989772923.USD","IE00BLSP4239.USD","BK4550","LU1116320737.USD","IXJ","BK4533","LU0985320562.USD","LU1430594728.SGD","LU0211331839.USD","SG9999014575.USD","LU2324357040.USD","HRTS","BK4534","LU1037948541.HKD","LU1929549753.HKD","IE00BJJMRZ35.SGD","LU0289739699.SGD","IE00B1BXHZ80.USD","PPH","XLV","LU1066051811.HKD","LU2125909247.SGD","SG9999014542.SGD","LU0130102774.USD","LU0868494708.USD","LU0265550946.USD","BK4588","SG9999001440.SGD","LU1941712348.USD","BK4007","LU1032466523.USD","BK4585","LU1934455277.USD","LU0861579265.USD","BK4516","JDOC","LU1061106388.HKD","SG9999002224.SGD","SG9999015358.SGD","LU0859254822.USD","LU1989772840.SGD","FHLC","SG9999002232.USD","LU0098860793.USD","LU0942090050.USD","LU2125154778.USD","LU1934455863.HKD","LU0124676726.USD","LU0432979614.USD","LU0477156953.USD","SG9999001176.USD","LU2112291526.USD","LU0058720904.USD","LU1093756168.USD","LU1066051225.USD","LU0689626769.HKD","SG9999013999.USD","IE00BBT3K403.USD","IE0009355771.USD","LU1066053197.SGD","IE000M9KFDE8.USD","LU0203347892.USD","IE00BSNM7G36.USD","LU1571399168.USD","LU2468319806.SGD","LU1917777945.USD","MRK","LU0106261372.USD","IE00BLSP4452.SGD","LU2491050071.SGD","SG9999014559.SGD","LU0122379950.USD","LU0265550359.USD","LU1934455194.USD","LU2106854487.HKD","LU0868494617.USD","LU2357627491.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194645441","title":"Stoke Therapeutics與渤健在第16屆歐洲癲癇大會上公布Zorevunersen長期臨床數據，力證Dravet綜合徵治療藥物的疾病修飾潛力","url":"https://stock-news.laohu8.com/highlight/detail?id=1194645441","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194645441?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 07:31","pubTimestamp":1788478271,"startTime":"0","endTime":"0","summary":"Stoke Therapeutics与渤健公司于第16届欧洲癫痫大会上联合呈现了Zorevunersen的长期临床数据，这些数据有力支持了这款用于治疗Dravet综合征的在研药物所具备的疾病修饰潜力。Zorevunersen作为一种实验性疗法，其最新公布的长期随访结果备受业界关注。此次大会上披露的数据，进一步印证了该药物在改变Dravet综合征疾病进程方面的可能性，为这一罕见且严重的癫痫性脑病治疗领域带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","IE00B19Z9P08.USD","BK4585","IE00B894F039.SGD","BIIB","BK4139","LU0889565916.HKD","BK4533","PBE","BK4532","IE00B19Z9Z06.USD","LU0234570918.USD","BK4588","LU0320765992.SGD","STOK","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664808013","title":"印度西普拉（Cipla）與中國齊魯製藥合作，在美國推出默克公司Keytruda的生物類似藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2664808013","media":"路透中文","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664808013?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 23:24","pubTimestamp":1788449052,"startTime":"0","endTime":"0","summary":"印度西普拉与中国齐鲁制药合作，在美国推出默克公司Keytruda的生物类似药路透9月3日-印度西普拉公司周四表示，其美国子公司与中国齐鲁制药达成独家合作协议，获得默克公司抗癌药物“Keytruda”生物类似药在美国市场的授权。详情如下：根据协议，齐鲁制药将负责对QL2107的研发、监管审批、生产和供应，而CiplaUSA将负责该药在美国的商业化及销售。默克公司持有的“Keytruda”专利保护将于2028年到期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nL4T44V1B7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0208291251.USD","LU0203345920.USD","LU2461242641.AUD","PAWZ","PPH","LU1430594728.SGD","LU1983299246.USD","IE00BSNM7G36.USD","IYH","IE00BLSP4452.SGD","LU1989772840.SGD","LU1934455194.USD","LU1585245621.USD","LU0122379950.USD","IE00B1BXHZ80.USD","LU2433249047.HKD","SG9999001440.SGD","LU0006306889.USD","LU0070302665.USD","LU1061106388.HKD","LU2491050154.USD","LU0211331839.USD","LU0058720904.USD","BK4585","IE00BBT3K403.USD","LU0098860793.USD","MRK","LU1032466523.USD","LU1989771016.USD","LU2361045086.USD","LU1093756325.SGD","XLV","LU1162221912.USD","LU2023250504.SGD","LU2468319806.SGD","SG9999014542.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","BK4516","SG9999013999.USD","LU0265550946.USD","LU0823416689.USD","BK4533","TRUH","LU0980610538.SGD","LU0965509010.AUD","LU0942090050.USD","VHT","LU2106854487.HKD","IE000M9KFDE8.USD","LU2357627491.SGD","LU0965509101.SGD","SG9999001176.SGD","LU2324357040.USD","LU1571399168.USD","LU1934455277.USD","LU2125909593.SGD","LU1066051811.HKD","LU1974910355.USD","BK4550","LU0965509283.SGD","HRTS","LU1069347547.HKD","LU1066051498.USD","LU1917777945.USD","LU0289739699.SGD","LU0320765646.SGD","CPLFY","LU2491050071.SGD","LU0238689110.USD","LU1941712264.USD","LU2112291526.USD","LU0868494617.USD","SG9999014567.USD","LU2089984988.USD","IE00B4R5TH58.HKD","LU0648001328.SGD","LU0130102774.USD","LU0130517989.USD","JDOC","IE00BN8TJ469.HKD","LU0234572021.USD","RXL","LU0965508806.USD","LU0689626769.HKD","LU0868494708.USD","LU2361044949.HKD","LU1037948897.HKD","BK4559","LU1923622614.USD","LU1934455863.HKD","LU0106261372.USD","SG9999015358.SGD","IE00BLSP4239.USD","BMED","FHLC","IHE","LU1699723380.USD","LU0124676726.USD","LU1035773651.USD","IE00BFTCPJ56.SGD","LU1066053197.SGD","IXJ","LU0477156953.USD","IE0009355771.USD","LU1989772923.USD","LU1929549753.HKD","IE00B2B36J28.USD","LU2361044865.SGD","LU0859254822.USD","LU0320765489.SGD","LU2023250843.SGD","SG9999014575.USD","LU1116320901.HKD","LU2491049909.HKD","LU0985320562.USD","LU1201861249.SGD","BK4534","LU2125909247.SGD","LU2360032135.SGD","LU0203347892.USD","LU0265550359.USD","SG9999002224.SGD","LU1037948541.HKD","LU0432979614.USD","LU1093756168.USD","LU1291159041.SGD","LU1941712348.USD","SG9999015341.SGD","BK4007","LU0861579265.USD","LU1066051225.USD","BK4588","LU0266013472.USD","LU2125154935.USD","SG9999001176.USD","LU1116320737.USD","LU1023059063.AUD","FTXH","IE00BJJMRZ35.SGD","SG9999014559.SGD","LU2125154778.USD","GDOC","LU1057294990.SGD","SGXZ57979304.SGD","SG9999002232.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664872008","title":"艾伯維公布CERVINO三期臨床試驗取得積極主要終點數據。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664872008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664872008?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 21:15","pubTimestamp":1788441323,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","IBBJ","BMED","MDTX","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664872828","title":"中國生物製藥(01177.HK)：TQB6426「GPC3 ADC」臨床試驗申請獲FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664872828","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664872828?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 20:42","pubTimestamp":1788439353,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","BK4588","IBBJ","IBBQ","PSYK","BMED","MDTX","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664874071","title":"中國生物製藥：附屬公司正大天晴自主研發的國家1類新藥TQB6426臨床試驗申請獲FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664874071","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664874071?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 20:41","pubTimestamp":1788439284,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","LABU","PSYK","BMED","BK4588","BK4585","IBBJ","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664820856","title":"ST人福：RFUS-949片進入II期臨床試驗研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2664820856","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664820856?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 16:37","pubTimestamp":1788424652,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PSYK","IBBJ","IBBQ","BMED","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664270568","title":"甘李藥業(603087.SH)獲得GZC8072片新適應症《藥物臨床試驗批准通知書》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664270568","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664270568?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 16:31","pubTimestamp":1788424286,"startTime":"0","endTime":"0","summary":"智通财经APP讯，甘李药业(603087.SH)发布公告，公司全资子公司甘李药业山东有限公司于近日收到国家药品监督管理局下发的关于在研药品GZC8072片的《药物临床试验批准通知书》，同意本品开展2型糖尿病适应症的临床试验。GZC8072片是甘李药业自主研发的新一代偏向型超长效多肽口服周制剂。该分子依托公司NovaPeptide多肽技术平台与SupOraTide口服多肽技术平台，在提升分子活性、延长半衰期的基础上，同时显著改善口服生物利用度，从而有望支持每周一次口服给药的方案。截至公告披露日，全球范围内尚无用于2型糖尿病的GLP-1口服周制剂片剂获批上市。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","PSYK","IBBQ","MDTX","603087","IBBJ","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664716827","title":"甘李藥業：GZC8072片獲2型糖尿病臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664716827","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664716827?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 16:29","pubTimestamp":1788424183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","IBBJ","IBBQ","PSYK","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664279758","title":"ST人福(600079.SH)：RFUS-949片進入II期臨床試驗研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2664279758","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664279758?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 16:12","pubTimestamp":1788423169,"startTime":"0","endTime":"0","summary":"智通财经APP讯，ST人福(600079.SH)发布公告，公司控股子公司宜昌人福药业有限责任公司(简称“宜昌人福”，公司持有其80%的股权)研发的RFUS-949片近日进入II期临床试验研究。试验名称：评价RFUS-949片用于腹部手术术后镇痛的多中心、随机、双盲、平行、安慰剂对照的疗效和安全性研究试验目的：评价RFUS-949片用于术后镇痛的疗效和安全性，探索RFUS-949片用于术后镇痛的用法用量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491467.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","PSYK","BK0188","BK0239","IBBQ","IBBJ","BMED","BK0185","MDTX","BK0070","600079","BK0096","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664802827","title":"瑞銀上調強生目標價至320美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664802827","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664802827?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 15:59","pubTimestamp":1788422345,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0994945656.USD","IHE","FTXH","UDN","FHLC","LU2112291526.USD","LU0124676726.USD","LU2430703095.HKD","TRUH","JNJ","LU0882574055.USD","IE00BJT1NW94.SGD","IE000F7OJYX1.SGD","LU2487616109.SGD","JDOC","IYH","VHT","LU1059921491.USD","IE00BKVL7J92.USD","LU0683600562.USD","IE00B1BXHZ80.USD","RXL","BK4007","BK4532","LU0234570918.USD","UUP","LU1221951046.USD","GDOC","IE00BVYPNV92.GBP","LU1244550577.SGD","LU1061106388.HKD","SGXZ80539844.SGD","LU1629891620.HKD","BK4585","LU0070217475.USD","MEDX","LU1496350502.SGD","IXJ","SG9999001176.SGD","LU2505996681.GBP","LU1023059063.AUD","LU1043141396.HKD","XLV","IE000BZT7R73.USD","PJP","IE000MB6IJN5.SGD","LU2133065610.SGD","BMED","SGXZ57979304.SGD","IE00BLSP4239.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664179318","title":"強生(JNJ)股票9月2日開盤上漲3.15%：釋放什麼信號？","url":"https://stock-news.laohu8.com/highlight/detail?id=2664179318","media":"TradingKey中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664179318?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 21:48","pubTimestamp":1788356898,"startTime":"0","endTime":"0","summary":"• 资金向医疗保健股等防御性板块轮动，推动强生股价上涨。\n• 滑石粉诉讼的进展与 FDA 批准提振了投资者信心，并助力其增长战略。\n• 公司公布了强劲的季度业绩，并上调了全年运营指引。","market":"hk","thumbnail":"https://resource.tradingkey.com/uploads/20250314/d38d57c8dfb24421a5b88ef27a9554e3shutterstock_2383470839_optimized_150.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/uploads/20250314/d38d57c8dfb24421a5b88ef27a9554e3shutterstock_2383470839_optimized_150.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/zh-hans/news/market-movers/262146572-market-movers-jnj-20260902","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JNJ","IE0009355771.USD","LU2896262040.SGD","IE000MB6IJN5.SGD","FHLC","VHT","IXJ","BK4559","IE00BSNM7G36.USD","IYH","IE00B19Z3B42.SGD","LU0882574055.USD","LU1196500208.SGD","IE0002141913.USD","IE00B3T34201.USD","IHE","LU0545562505.USD","LU1430594728.SGD","LU1585245621.USD","LU1718418525.SGD","BK4007","MEDX","IE00B1BXHZ80.USD","LU1121112475.USD","LU0820561909.HKD","LU2129689431.USD","GDOC","LU1894683264.USD","LU1674673428.USD","IE00BN8TJ469.HKD","LU1914381329.SGD","BK4550","LU1032955483.USD","LU2023250330.USD","BK4532","LU2592432038.USD","PJP","LU0345769128.USD","IE00BGHQF631.EUR","LU1057294990.SGD","FTXH","LU2471134796.USD","LU0426412945.USD","BMED","XLV","RXL","LU1228905540.USD","LU2756315664.SGD","JDOC","TRUH"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}]}}